Skip to main content
. 2026 Jan 1;16(6):2952–2983. doi: 10.7150/thno.124189

Figure 6.

Figure 6

In vitro phagocytosis and ex vivo analysis of immune cell activation. (A) Schematic representation of the experimental setup. (B) Quantification of the phagocytosis rate (%) of macrophages after treatment with RSL3, STS, MCT-NE#9, and CU-CPT22, analyzed by flow cytometry. Values are shown as mean ± SEM (n = 3 per group). (C) Representative flow cytometry dot plots showing phagocytosis of 4T1 cells by Raw 264.7 macrophages under different treatment conditions. (D) Quantification of the phagocytosis rate (%) of Raw 264.7 macrophages following different treatments. (E, F) Quantification and histogram representation of MHC class I expression on CD11b+ cells after MCT-NE#9 and CU-CPT22 treatment. (G, H) Quantification and histogram representation of CD86 expression on CD11b+ cells after MCT-NE#9 and CU-CPT22 treatment. (I, J) Quantification and histogram representation of MHC II class expression on CD11b+ cells after MCT-NE#9 and CU-CPT22 treatment. (K, L) Quantification and histogram representation of iNOS expression on CD11b+ cells after MCT-NE#9 and CU-CPT22 treatment. (M) Quantification of Tregs in the splenocyte co-culture system after treatment with MTD, MCT, and MCT-NE#9. (N) Quantification of M1 macrophages in the splenocyte co-culture system after treatment with MTD, MCT, and MCT-NE#9. (O) Quantification of macrophage-mediated antigen presentation in the splenocyte co-culture system after treatment with MTD, MCT, and MCT-NE#9. (P) Quantification of dendritic cell-mediated antigen presentation in the splenocyte co-culture system after treatment with MTD, MCT, and MCT-NE#9. Values are shown as mean ± SEM (n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.